Retrospective Multi-cohort Study of Frontline Afatinib Followed by 2nd Line Therapy Including Osimertinib, Chemotherapy or Other Therapy

NCT04930133 · clinicaltrials.gov ↗

UNKNOWN

Status

737

Enrollment

OTHER

Sponsor class

Conditions

NSCLC

Interventions

DRUG: Gilotrif

Sponsor

Seoul St. Mary's Hospital

Collaborators

[object Object]